We are live on ! Find out more

CNS Pharmaceuticals

CNSP

Market cap $8.33M

5.70 USD

0.00

0%

At close Updated Sep 15, 11:03 AM EDT

1 day

0%

5 days

-3.23%

1 month

5.56%

3 months

20.25%

6 months

132.65%

Year to date

7.55%

1 year

-38.04%

5 years

-100%

10 years

-100%

About: CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.

Employees: 8

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth

Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" Segment Access the segment here HOUSTON, TX / ACCESS Newswire / September 1, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment. Dylan Wenke, Chief Business Officer of CNS Pharmaceuticals, provided an update on its business development strategy as part of its broader transformation as the Company works to establish a pipeline focused on oncology or neurology with best in class potential.

CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth

CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference

Video webcast now available here HOUSTON, TX / ACCESS Newswire / August 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in the Virtual Investor "Why Now" on-demand conference. Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's strategic transformation that is being built on the strength of its newly assembled executive leadership team, enhanced financial position following its recent financing, and disciplined approach to evaluating differentiated assets.

CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation

Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline HOUSTON, TX / ACCESS Newswire / August 12, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2026 and provided an update on the corporate strategy the company introduced in March 2026. "We are moving with speed and discipline to transform this company," said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals.

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation

CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment

Access the segment here HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment. Steve O'Loughlin, Chief Financial Officer of CNS Pharmaceuticals, discussed the Company's recently completed oversubscribed $22.5 million financing in the virtual segment, addressing the factors that enabled the successful capital raise following its strategic reset and acquisition-focused transformation.

CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment

CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress

Access the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's recent $22.5 million financing, including its strategic pivot, progress made to date and how the capital positions CNS to identify and advance new assets aimed at driving long-term shareholder value.

CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress

24/7 Wall Street

Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6

CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story.

Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6

CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress

Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently announced corporate strategy Company actively evaluating multiple acquisition opportunities while advancing discussions to out-license its legacy glioblastoma multiforme programs, Berubicin and TPI-287 New executive leadership team assembled in the first quarter continues to demonstrate rapid execution against strategy HOUSTON, TX / ACCESS Newswire / May 14, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update highlighting the Company's ongoing strategic transformation and execution progress. The first quarter of 2026 marked the beginning of a significant strategic shift for CNS Pharmaceuticals, including the appointment of a new Chief Executive Officer and executive leadership team, the launch of a new corporate strategy, the repositioning of the Company toward an acquisition-driven growth strategy focused on differentiated clinical-stage assets in neurology and oncology and the decision to seek out-licensing opportunities for its legacy glioblastoma multiforme programs, Berubicin and TPI-287.

CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress

What's Going On With CNS Pharmaceuticals Stock On Wednesday?

CNS Pharmaceuticals Inc. (NASDAQ:CNSP) shares are up during Wednesday's premarket session.

What's Going On With CNS Pharmaceuticals Stock On Wednesday?

Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot

CNS Pharmaceuticals Inc. (NASDAQ:CNSP) shares are up during Monday's premarket session following the announcement of an oversubscribed private placement financing expected to generate approximately $22.5 million.

Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot

CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing

The private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners Proceeds expected to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently announced corporate strategy HOUSTON, TX / ACCESS Newswire / May 4, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, announced today that it has entered into securities purchase agreements for a private placement financing that is expected to result in gross proceeds of approximately $22.5 million to the Company, before placement agent fees and offering expenses. The private placement includes participation from institutional healthcare investors, including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners.

CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing

See News Rankings

Price charts implemented using Lightweight Charts™